The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prophylactic cranial irradiation after reaching complete response, partial response, or stable disease in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (ProACT).
Amanda Tufman
Honoraria - Roche
Other Remuneration - AstraZeneca; Roche
Claus Belka
Honoraria - AstraZeneca; Roche
Other Remuneration - AstraZeneca; Roche
Heike Kuenzel
No relevant relationships to disclose
Rudolf M. Huber
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; Roche
Other Remuneration - AstraZeneca (I); Roche